Organization (Industry)
MERCK & CO., INC.
ClinicalTrials.gov lists MERCK & CO., INC. as lead sponsor of 2,161 trials, counting the companies grouped under it. MERCK & CO., INC. itself has 9 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Merck & Co., via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers MERCK & CO., INC. and 6 companies grouped under it: 2,161 lead-sponsored trials (0 its own, 2,161 in the grouped companies) and 8 legal-entity registrations (3 its own, 5 in the grouped companies).
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Companies grouped under this page (6)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Merck Sharp & Dohme LLC | 2,155 | 2 |
| MSD Italia S.r.l. | 3 | 0 |
| MSD R&D (China) Co., Ltd. | 2 | 0 |
| MSD Korea Ltd. | 1 | 0 |
| Acceleron B.V. | 0 | 2 |
Showing 5 of 6 member companies.
Disease areas (226)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Hepatitis C | 20 |
| Glioma | 17 |
| Glioblastoma | 16 |
| Brain Neoplasms | 15 |
| Pulmonary Disease, Chronic Obstructive | 15 |
Showing 5 of 226 disease areas.
Trials by start year as sponsor or collaborator (17)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2012 | 2 |
| 2011 | 2 |
| 2010 | 5 |
| 2009 | 9 |
| 2008 | 19 |
| 2007 | 26 |
| 2006 | 18 |
| 2005 | 27 |
| 2004 | 8 |
| 2003 | 5 |
Showing 10 of 17 years.
Recruitment duration, a model prediction: none of the 10 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (9)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Peginterferon Alfa-2B | 3 |
| Ribavirin | 2 |
| Mometasone Furoate Nasal Spray | 1 |
| Fluconazole | 2 |
| Posaconazole | 2 |
Showing 5 of 9 approved assets.
Journals published in (194)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Antimicrobial agents and chemotherapy | 18 |
| Annals of the rheumatic diseases | 16 |
| Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 15 |
| The New England journal of medicine | 15 |
| Hepatology (Baltimore, Md.) | 14 |
Showing 5 of 194 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 5,084 | 4 | 2024-02-27 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 65,011,000,000 | 18,254,000,000 | 15,789,000,000 |
| 2024 | 64,168,000,000 | 17,117,000,000 | 17,938,000,000 |
| 2023 | 60,115,000,000 | 365,000,000 | 30,531,000,000 |
| 2022 | 59,283,000,000 | 14,519,000,000 | 13,548,000,000 |
| 2021 | 48,704,000,000 | 13,049,000,000 | 12,245,000,000 |
| 2020 | 41,518,000,000 | 7,067,000,000 | 13,397,000,000 |
| 2019 | 39,121,000,000 | 9,843,000,000 | 9,724,000,000 |
| 2018 | 42,294,000,000 | 6,220,000,000 | 9,752,000,000 |
| 2017 | 40,122,000,000 | 2,394,000,000 | 10,339,000,000 |
| 2016 | 39,807,000,000 | 3,920,000,000 | 10,261,000,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (39)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-05-22 | Debt financing | 500,000,000 | Sec extracted |
| 2026-05-22 | Debt financing | 1,000,000,000 | Sec extracted |
| 2026-05-22 | Debt financing | 500,000,000 | Sec extracted |
| 2026-05-22 | Debt financing | 1,000,000,000 | Sec extracted |
| 2026-05-22 | Debt financing | 1,500,000,000 | Sec extracted |
Showing 5 of 39 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 29 |
FDA recalls (5)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Belsomra (suvorexant) tablets, 10mg, 30 Tablets in 3 Blister Cards per Carton, Each Blister Card contains 10 Tablets, Rx only, Merck Sharp & Dohme LLC, Rahway, NJ 07065, USA, NDC 0006-0033-10 (Shellpack and Print Mat Labels), 0006-0033-30 (Carton Label) | Class II | 2025-07-21 |
| Liptruzet (ezetimibe and atorvastin) tablets,10 mg/10 mg, a) 30 count blister (NDC 66582-320-30), b) 90 count blister (NDC 66582-320-54), Rx only, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Whitehouse Station, NJ 08889 | Class III | 2014-01-13 |
| Liptruzet (ezetimibe and atorvastin) tablets,10 mg/20 mg, a) 30 count blister (NDC 66582-321-30), b) 90 count blister (NDC 66582-321-54), Rx only, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Whitehouse Station, NJ 08889 | Class III | 2014-01-13 |
| Liptruzet (ezetimibe and atorvastin) tablets,10 mg/40 mg, a) 30 count blister (NDC 66582-322-30), b) 90 count blister (NDC 66582-322-54), Rx only, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Whitehouse Station, NJ 08889 | Class III | 2014-01-13 |
| Liptruzet (ezetimibe and atorvastin) tablets,10 mg/80 mg, a) 30 count blister (NDC 66582-323-30), b) 90 count blister (NDC 66582-323-54), Rx only, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Whitehouse Station, NJ 08889 | Class III | 2014-01-13 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 44 | 2026-08-06 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Schering-Plough Corporation | Miami Lakes, US | Health Canada |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | 2045 |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (95)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Centocor, Inc. | Co sponsors trial with | 10 |
| M.D. Anderson Cancer Center | Co sponsors trial with | 10 |
| Government of the United States of America | Co sponsors trial with | 10 |
| Mass General Brigham | Co sponsors trial with | 8 |
| Roche (Switzerland) | Co sponsors trial with | 7 |
Showing 5 of 95 relationships.
Latest dated events (5,613)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09-16 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-06 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-05-22 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-05-22 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-05-22 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 5,613 events.
CLIA clinical laboratory certificates (1)
| Lab | Certificate | Status |
|---|---|---|
| MERCK AND COMPANY | Certificate of waiver | Active |
Biomarker capability evidence (405)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCC6 | Trial collaborator | Named in trial inclusion criteria |
| AFP | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 405 evidence rows.
On Scientist.com
MERCK & CO., INC. is listed as a research supplier in the Scientist.com network.
Service areas
In June, 2012, Cubist announced the Company’s five-year strategic aspirations — Building Blocks of Growth. The Company’s five-year roadmap, including goals for top- and bottom-line growth, future pipeline developments, and cultural elements will position Cubist to deliver long-term, sustainable growth. Cubist has established itself as a global leader in the acute care/hospital environment. Our Building Blocks of Growth will help the company build on this momentum as we look to deliver important new medicines for patients and drive long-term value for our customers and shareholders...
Show the full description
In June, 2012, Cubist announced the Company’s five-year strategic aspirations — Building Blocks of Growth. The Company’s five-year roadmap, including goals for top- and bottom-line growth, future pipeline developments, and cultural elements will position Cubist to deliver long-term, sustainable growth. Cubist has established itself as a global leader in the acute care/hospital environment. Our Building Blocks of Growth will help the company build on this momentum as we look to deliver important new medicines for patients and drive long-term value for our customers and shareholders. The Building Blocks of Growth reflects what sets Cubist apart and will help us sharpen our organizational focus through 2017. - See more at: http://www.cubist.com/about/#sthash.rcTbAu8U.dpuf
- Website
- www.cubist.com
Not on this page
Checked, with nothing recorded for this organization: active development programs, sponsor delivery record, fda warning letters, fda untitled letters, and biomarkers this organization publishes on.
Work with Cubist Pharmaceuticals on Scientist.com
For prices, more details, or to contact Cubist Pharmaceuticals, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.